Targacept, Inc. 200 East First Street, Suite 300 Winston-Salem, NC 27101-4165 Therapeutic Focus:  Nervous system diseases and disorders Therapeutic Targets:  Neuronal nicotinic receptors (NNRs), which are key regulators of the nervous system Product Candidates:  TC-5214, major depressive disorder; TC-5619, cognitive dysfunction in schizophrenia, ADHD and potentially Alzheimer's disease; AZD3480, attention deficit/hyperactivity disorder (ADHD); AZD1446, Alzheimer's disease; and TC-6987 for inflammatory disorders.

President & CEO:  J. Donald deBethizy, Ph.D. Number of Employees:  136                                    Date Established:  March 1997 IPO Completed:  April 2006 NASDAQ Ticker Symbol:  TRGT

Strategic Alliances:

Global collaboration and license agreement with AstraZeneca for TC-5214 for the treatment of major depressive disorder.

Exclusive global license and research collaboration with AstraZeneca AB for the development and commercialization of AZD3480 to treat ADHD and AZD1446 to treat Alzheimer's disease. 

 Intellectual Property:  Pentad^TM, a proprietary drug discovery platform; and an extensive patent estate covering compounds that act on NNRs

Founders:

• J. Donald deBethizy, Ph.D., President & Chief Executive Officer
• Merouane Bencherif, M.D., Ph.D., Senior Vice President, Preclinical Research
• William S. Caldwell, Ph.D., Senior Vice President, Drug Discovery and Development
• Patrick M. Lippiello, Ph.D., Senior Principal Scientist